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MYOCARDIAL STUNNING: A 
THERAPEUTIC CONUNDRUM 
Dobutamine and pyruvate are two inotropic agents with different mecha- 
nisms of action. Although both agents alter postischemic myocardial 
dysfunction, their potential metabolic effects in the setting of in vivo 
myocardial stunning have not been addressed. In this study, the effects of 
dobutamine and pyruvate on systolic wall thickening, myocardial phos- 
phorylation potential index, interstitial fluid adenosine level, and myocar- 
dial oxygen consumption in in vivo stunned porcine myocardium were 
assessed. Stunning was induced with a 10-minute occlusion of the left 
anterior descending coronary artery. After 30 minutes of reperfusion, pigs 
were treated with either intravenous dobutamine (10/~g/kg per minute) or 
intracoronary pyruvate (1 ml/min, 150 mmol/L solution, pH 7.4). Infusion 
of both agents resulted in a marked improvement in regional systolic wall 
thickening. The dobutamine ffect, however, produced a marked increase in 
myocardial oxygen consumption and was associated with an increase in 
interstitiai adenosine caused by myocardial de-energization, because the 
myocardial phosphorylation potential index ratio decreased from 0.17 -- 
0.02 to 0.09 -+ 0.02 (p < 0.05). In contrast, pyruvate enhanced myocardial 
energy status, because the myocardial phosphorylation potential index 
ratio increased from 0.20 _+ 0.03 to 0.55 _ 0.08 (p < 0.01). These 
experimental findings suggest hat under certain circumstances the use of 
/3-receptor agonists to treat myocardial stunning may be suboptimal, if not 
undesirable. Further investigation is warranted to determine the optimum 
therapy for the stunned heart. (J THORAC CARDIOVASC SURG 1995;110: 
1391-1401) 
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R eversible myocardial contractile dysfunction af- ter a short period of ischemia is referred to as 
myocardial Stunning. Although difficult to quantify, 
it is known that myocardial stunning occurs after 
coronary thrombolysis and heart operations. 1 Stunned 
myocardiurn can persist for hours to days, thus 
inotropic support is often needed uring this critical 
period, particularly when there is an associated 
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limitation in myocardial reserve. Although the un- 
derlying mechanisms are still a topic of controversy, 
substantial evidence suggests that myocardial stun- 
ning may be related to ischemic alcium overload, 2 
impaired calcium handling by the sarcoplasmic re- 
ticulum, 3and reduced calcium sensitivity of contrac- 
tile proteins during reperfusion. 4 These pathophy s- 
iol0gic changes provide the basis for current 
inotropic therapy with agents such as dobutamine 
and dopamine, which increase contractility by in- 
creasing intracellular calcium levels. 
Although dobutamine increases contractility in 
the stunned myocardium, other effects associated 
with its administration may not be beneficial. The 
inotropic effect of dobutamine has been reported to 
be associated with low energy efficiency (oxygen- 
wasting effects) in isolated and normal human 
hearts.5, 6 This effect may be exacerbated in stunned 
myocardium because sarcoplasmic reticulum Ca 2+ 
adenosinetriphosphatase (ATPase) activity is re- 
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duced in the postischemic heart)  In addition,/3-ad- 
renergic agonists further reduce myofibril calcium 
sensitivity, which is thought to be depressed in 
stunned myocardium. 4 
The inotropic effect of dobutamine is associated 
with increased myocardial adenosine release in in 
vivo experiments, 7 which suggests that treatment 
with this agent reduces the oxygen supply versus 
demand ratio. Increased adenosine release is in- 
versely related to myocardial phosphorylation po- 
tential, which monitors the Gibbs free energy 
change of ATP hydrolysis,  Gibbs free energy serves 
as the driving force for energy-dependent ATPases, 
such as the sarcoplasmic reticulum Ca2---ATPase, 
which has the highest energy demand. Myocardial 
phosphorylation potential is primarily determined 
by the [ATP]/[ADP]" [Pi] ratio, where brackets in- 
dicate the free intracellular concentration of these 
metabolites (ADP, adenosine diphosphate; Pi, inor- 
ganic phosphate). Because of the difficulty of di- 
rectly measuring tissue free ADP content, the myo- 
cardial phosphorylation potential index (CrP/Cr. Pi) 
ratio has been accepted as an index of myocardial 
phosphorylation potential (CrP, creatine phosphate; 
Cr, creatine; Pi, inorganic phosphate). 9' 10 Because 
dobutamine increases interstitial adenosine con- 
centration, it is possible that dobutamine decreases 
phosphorylation potential. Although norepineph- 
rine has been reported to decrease phosphorylation 
potential in isolated guinea pig hearts, 1° the effect of 
dobutamine on phosphorylation potential in in vivo 
stunned myocardium has not been determined. 
Pyruvate has also been shown to be an effective 
positive inotropic agent in normal and stunned 
myocardium.lO, 11 Pyruvate is an excellent energy 
substrate that exerts its inotropic effects, not by 
receptor activation, but presumably by altering cy- 
tosolic or mitochondrial redox potential. 1°-12 The 
combination of enhancing myocardial phosphoryla- 
tion potential and contractility may be valuable in 
the treatment of stunned myocardium, which may 
have impaired energy metabolism. The purpose of 
this study was to evaluate the different effects of 
dobutamine and pyruvate in in vivo stunned myo- 
cardium and to assess their effects on myocardial 
phosphorylation potential. 
Methods 
All animals received humane care in compliance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Animal preparation. Domestic pigs of either sex weigh- 
ing 25 to 35 kg were used. Anesthesia was induced with 
ketamine (30 mg/kg, intramuscularly), followed by sodium 
pentobarbital (15 mg/kg, intravenously through an ear 
vein). Anesthesia was then maintained with sodium pen- 
tobarbital (10 to 15 mg/kg per hour). A tracheostomy was 
done and the lungs were mechanically ventilated with a 
mixture of room air and 100% 02. Tidal volume, respira- 
tory rate, and percent oxygen in the inspired air were 
adjusted to maintain normal arterial blood gas and pH 
values. Core body temperature was monitored with an 
esophageal temperature probe and maintained at 38.0 °to 
39.0 ° C with a heating pad. The right femoral artery was 
cannulated for withdrawal of samples for blood gas deter- 
minations and for monitoring blood pressure. The femo- 
ral vein was cannulated for the infusion of fluids and for 
the maintenance of anesthesia. 
The anterior chest wall was removed, the pericardium 
incised, and the heart suspended in a pericardial cradle. 
Left ventricular pressure was measured with a Millar 
catheter (Millar Instruments Inc., Houston, Tex.) placed 
through the ventricular wall in the apical region. Changes 
in left ventricular pressure with respect o time (dP/dt) 
were determined by differentiation of left ventricular 
pressure. In preparation for coronary artery occlusion, a 
2 cm portion of the proximal region of the left anterior 
descending coronary artery (LAD) was dissected and a 
modified 24-gauge angiographic catheter was inserted into 
the LAD distal to the occluder with the tip facing down- 
stream. Coronary blood flow was measured with an ultra- 
sonic flow probe (Transonic Systems Inc., Ithaca, N.Y.) 
placed around the proximal portion of the LAD distal to 
the occluder. 
Regional ventricular function. Systolic wall thickening 
(SWT) was used as an indicator of regional ventricular 
function. Sonomicrometric measurements of left ventric- 
ular wall thickness were made with pairs of piezoelectric 
crystals. One of the crystals was inserted at a 45-degree 
angle into the endocardium (ideally this crystal ends up 
situated in the innermost endocardial layer) and the 
second crystal, which is incorporated into a Dacron fabric 
patch, was sewn onto the epicardium at the location 
indicating shortest distance between the two crystals. The 
position of the crystal in the ischemic area was verified by 
a 40-second occlusion of the LAD. Pairs of crystals were 
placed in both the LAD and left circumflex coronary 
artery perfused beds, the latter area serving as a nonisch- 
emic time control. 
Cardiac microdialysis. Interstitial fluid adenosine, in- 
osine, and hypoxanthine l vels were measured with a 
microdialysis fiber developed in this laboratory. 7 The 
dialysis fiber has a 2.0 cm exchange window and molecular 
cutoff size of 2000 dalton. Dialysis fibers were placed in 
the LAD and left circumflex coronary artery perfused 
beds. The dialysis fiber was perfused at 2 /xl/min with 
Krebs buffer (gassed with 5% CO2 and 95% N2 to 
minimize 0 2 delivery). Samples were collected over a 
10-minute period, except during ischemia when two 
5-minute samples were collected. Samples were stored at 
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-80 ° C before analysis. Dialysate purine concentrations 
were determined by high-performance liquid chromatog- 
raphy as previously described. 7 
Determinat ion  of myocard ia l  t issue metabol i tes .  To 
determine tissue ATP, creatine phosphate, creatine, and 
inorganic phosphate l vels, biopsy samples were taken by 
means of a rapid-freezing biopsy drill (Alko Diagnostics 
Co., Holliston, Mass.). 13 The biopsy system consisted of 
an air-driven drill, a 2 mm diameter bore, and a vacuum 
line at -20 mm Hg pressure to cut and pull a 20 to 60 mg 
transmural myocardial sample into a reservoir of isopen- 
tane (approximately -100 ° C) precooled by liquid nitro- 
gen, such that the sample is cut and frozen in less than 1 
second. Immediately after the biopsy sample was ob- 
tained, the reservoir was checked to verify that the tissue 
plug was frozen in the isopentane. Only samples that were 
cut and frozen instantly in the isopentane were used for 
analysis. Frozen samples were stored at -80 ° C until they 
were processed. The first biopsy sample was taken in the 
apical region to avoid altering blood supply to the proxi- 
mal region where the second biopsy sample was taken. 
The distance between the biopsy sites was approximately 
1 cm. 
Frozen samples were trimmed to a size of approxi- 
mately 30 rag, rapidly weighed, then homogenized in 2.0 
ml 0.3N ice;cold perchloric acid solution with use of a 
Teflon rod (Glas-Col Instruments, Terre Haute, Ind.). 
The acid homogenates were centrifuged for 10 minutes at 
10,000 rpm (approximately 9200 g), and 1.5 ml of the 
resulting supernatant was neutralized with IN KOH. The 
pH was adjusted to 5.5 to 6.0 with a pH electrode, which 
was rinsed between samples with deionized istilled water. 
After 30 minutes on ice, the potassium perchlorate was 
removed by centrifugation and the supernatant s ored at 
- 80 ° C. 
Creatine phosphate and ATP were measured by a 
modified ion pair reverse-phase high-performance liquid 
chromatography method as described by Cordis. 14 Neu- 
tralized extracts were injected into a Cls reverse-phase 
column and eluted with a linear gradient of 100% buffer A 
(75 mmol/L KH2PO 4 plus 2 mmol/L tetrabutylammonium 
hydrogen sulfate, pH 5.5) to 40% buffer B (50% acetoni- 
trile) in 15 minutes at a flow rate of 2.0 ml/min. Peaks 
were quantified by peak area with the use of MAXIMA 
820 softward (Waters Instruments, Milford, Mass.). Myo- 
cardial adenine nucleotide contents were expressed as 
micromoles per gram wet weight. 
Inorganic phosphate was determined by a standard 
enzymatic method as previously described by Bringer and 
associates.iS This method is based on the stoichiometric 
phosphorylafion of glycogen by inorganic phosphate by 
means of glycogen phosphorylase toyield glucose-l-phos- 
phate, which is then converted to glucose-6-phosphate. 
The oxidation of glucose-6-phosphate by glucose-6-phos- 
phate dehydrogenase r sults in the reduction of the 
oxidized form of nieotinamide-adenine dinucleotide phos- 
phate; the increase in absorbance difference at 340 nm 
caused by the formation of the reduced form of nicotin- 
amide-adenine dinucleotide phosphate is directly propor- 
tional to the amount of inorganic phosphate present. 
Freeze-thawlng of extracts, which is known to cause 
nonenzymatic creatine phosphate breakdown, was limited 
to 1 to 2 cycles to minimize artifact increases in creatine 
and inorganic phosphate l vels. 
Creatine content was determined by a standard enzy- 
matic method described by Bringer and associates. 15Cre- 
atine kinase in the presence of ATP catalyzes the conver- 
sion of creatine to creatine phosphate and ADP, which is 
then converted to ATP and pyruvate in the presence of 
phospho(enol)pyruvate nd pyruvate kinase. Pyruvate is 
converted to lactate via lactate dehydrogenase; the oxida- 
tion of nicotinamide-adenine dinucleotide phosphate to 
the oxidized form of nicotinamide-adenine dinucleotide 
and the resulting decrease in absorbance at 340 nm is 
proportional to the amount of creatine. 
Genera l  protocol .  After instrumentation, the prepara- 
tion was stabilized for a minimum of 30 minutes. In the 
animals (n =14) in which dialysis fibers were used, 90 
minutes of equilibration was allowed after fiber insertion 
to allow dialysate purinc levels to stabilize. After baseline 
hemodynamic and metabolic data were obtained, myocar- 
dial ischemia was induced by 10 minutes of complete LAD 
occlusion. Lidocaine (3 mg/kg) was given intravenously 
before the clamp was released to reduce the occurrence of 
ventricular fibrillation. After 30 minutes of reperfusion, 
either intracoronary sodium pyruvate (1 ml/min, 150 
mmol/L, pH 7.4) or intravenous dobutamine (10/zg/kg per 
minute) was infused for 10 minutes and hemodynamic 
effects were recorded. The treatment was then terminated 
and the animals were monitored for an additional 20 
minutes. 
Series 1. In this series of experiments, the effects of 
dobutamine (n = 7) and pyruvate (n = 7) on hemody- 
namics and interstitial purines were assessed. Baseline 
hemodynamic measurements and dialysate purine sam- 
ples were collected during the 10 minutes immediately 
preceding coronary occlusion. Two 5-minute dialysate 
samples were taken during ischemia, and reperfusion 
samples were collected every 10 minutes for 1 hour of 
reperfusion. A small catheter was inserted into the great 
cardiac vein draining the LAD perfused bed to obtain 
coronary venous blood samples during the treatments for 
the determination of myocardial oxygen consumption. 
The venous amples were analyzed by a Ciba-Corning 288 
blood gas system (Medfield, Mass.) for oxygen tension, 
carbon dioxide tension, HCO3-, and oxygen content. 
Series 2. Biopsy samples were obtained in a separate 
series of experiments (n = 7/group) to avoid biopsy 
drill-induced alterations in function and interstitial me- 
tabolites. Biopsy samples were taken from the LAD 
perfused area after 30 minutes of reperfusion before 
either dobutamine or pyruvate infusion. Twenty minutes 
were allowed to let the animal recover from the transient 
regional trauma associated with the biopsy drill. Intrave- 
nous dobutamine (10/xg/kg per minute) or intracoronary 
pyruvate (1 ml/min, 150 mmol/L, pH 7.4) was then infused 
and biopsy samples were taken after 10 minutes of 
infusion. 
At the conclusion of both series of experiments, the 
animals were killed with an intravenous injection of 
sodium pentobarbital nd saturated KC1. The hearts were 
removed, and the placement of the crystals and dialysis 
fibers was carefully examined. The ischemic area was 
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Table I. Effects of dobutarnine and pyruvate on systemic hemodynamics and LAD blood flow 
HR (beats/rnin) MAP (rnrn Hg) LVEDP (ram Hg) CBF (ml/rnin) 
Dobutamine 
Baseline 95 ± 4 83.4 ± 2.8 4.6 ±: 1.1 17.3 ± 1.5 
30' RP 95 ± 4 79.8 -+ 3.8 5.3 ~+ 1.8 18.4 _+ 1.4 
10' DOB 149 _+ 14' 79.8 ± 4.0 4.7 + 1.4 28.7 ± 1.7" 
20' Recovery 94 + 3 76.5 ± 3.1 5.1 + 1.5 16.7 _+ 1.3 
Pyruvate 
Baseline 102 ± 10 83.4 _+ 2.8 4.0 + 1.4 17.6 ± 1.2 
30' RP 105 +_ 9 79.8 +- 3.8 4.1 ± 1.4 14.4 _+ 1.2 
10' PYR 105 _+ 9 79.7 ± 4.0 3.4 ± 1.3 15.7 ± 1.2 
20' Recovery 110 ± 10 76.5 ± 3.1 3.3 ___ 1.6 15.1 ± 1.2 
HR, Heart rate; MAP, mean arterial blood pressure; LVEDP, left ventricular end-diastolic pressure; CBF, coronary blood flow; Baseline, before ischemia; 30' 
RP, 30 minutes of reperfusion; 10' DOB, 10 minutes of intravenous dobutamine infusion; 10' PYR, 10 minutes of intracoronary pyruvate infusion, 20' Recovery, 
20 minutes after cessation of drug administration. Values are expressed as mean plus or minus standard error of the mean. 
Up < 0.05 versus 30 minutes of reperfusion. 
confirmed by injection of India ink into the LAD at the 
site of occlusion. 
Data analysis. Hemodynamic data were recorded on 
an 8-channel recorder. For the computation of SWT, end 
diastole was defined as the onset of positive dP/dt and end 
systole was taken as 20 msec before peak negative dP/dt. 
From the measurements of end-systolic wall thickness 
(ESWT) and end-diastolic wall thickness (EDWT), wall 
thickness changes were calculated as AWT = ESWT - 
EDWT and expressed as relative wall thickening by the 
formula %WT = &WT/EDWT. 100%. Values of post- 
ischemic relative wall thickening were then normalized to 
percent of preischemia levels. Myocardial oxygen con- 
sumption was calculated as (arterial 02 content - venous 
02 content) x (LAD blood flow). 
Statistical analysis. Values are expressed as mean plus 
or minus the standard error of the mean. The data were 
first analyzed by multivariate repeated analysis of vari- 
ance. Differences between the time points were compared 
with linear contrast. All calculations were done with the 
SAS procedure PROC GLM (SAS Institute, Inc., Cary, 
N.C.). A p value of less than 0.05 was considered as 
significant. 
Results 
In series 1 experiments, heart rate, mean arterial 
blood pressure, left ventricular end-diastolic pres- 
sure, and LAD blood flow were similar in both 
groups before ischemia and after 30 minutes of 
reperfusion (Table I). After 10 minutes of intrave- 
nous infusion, dobutamine significantly increased 
heart rate and LAD blood flow, but had no effect on 
mean arterial blood pressure or left ventricular 
end-diastolic pressure. Heart rate and coronary 
blood flow returned to preinfusion levels after a 
20-minute washout of dobutamine. In contrast, 10 
minutes of intracoronary pyruvate infusion had no 
significant effects on systemic hemodynamics. 
Regional ventricular function. The effects of 
ischemia, dobutamine, and pyruvate on SWT are 
illustrated in Fig. 1. Before ischemia there were no 
differences between the two groups with respect o 
absolute LAD SWT (32.3% + 3.6% versus 27.7% _+ 
2.4%). Ten minutes of LAD occlusion and 30 min- 
utes of reperfusion resulted in similar decreases in 
SWT: 31.2% _+ 1.0% and 30.0% _+ 1.2% of pre- 
ischemic values, respectively. Regional function in 
the nonischemic left circumflex artery perfused bed 
remained stable throughout he ischemia-reperfu- 
sion period. After 30 minutes of reperfusion left 
circumflex artery SWT was 91.3% _+ 3.8% and 
94.2% + 4.5% of baseline values in the dobutamine- 
and pyruvate-treated animals, respectively. 
Postischemic ntravenous dobutamine infusion in- 
creased SWT in the stunned myocardium from 
31.2% _+ 1.0% to 57.3% _+ 5.4% of baseline. Twenty 
minutes after cessation of the dobutamine infusion, 
the SWT value was lower than preinfusion values: 
21.7% _+ 2.3% versus 31.2% _+ 1.0% (p < 0.05). 
Intravenous dobutamine also increased SWT in the 
left circumflex artery nonischemic ontrol region; 
however, 20 minutes after the dobutamine treat- 
ment was discontinued, the SWT value in the left 
circumflex artery bed was similar to preinfusion 
values (94.8% ___ 6.3% versus 91.3% _ 3.8% of 
baseline SWT). 
Intracoronary pyruvate infusion resulted in a 
more than twofold increase in SWT (31.0% _+ 4.5% 
to 75.2% _+ 10.8% of preischemic values, p < 0.01). 
During pyruvate washout, SWT levels gradually 
returned to, but did not fall below, preinfusion 
levels. Intracoronary pyruvate infusion did not alter 
SWT values in the left circumflex artery control bed 
during and after the LAD coronary infusion. 
Myocardial oxygen consumption. The effects of 
dobutamine and pyruvate on myocardial oxygen 
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Fig. 1. Effects of ischemia (ISCH), reperfusion (30' RP), and intravenous dobutamine (DOB) and 
intracoronary p ruvate (PYR) infusions on SWT. SWT is expressed as percent of baseline (Base) values 
before ischemia. Values are expressed as mean plus or minus standard error of mean. *p < 0.05 versus 
reperfusion. 
consumption are illustrated in Fig. 2. The myocar- 
dial oxygen consumption was the same for both 
groups before ischemia (7.3 _+ 0.2 versus 7.1 _+ 0.2 
ml/min per 100 gin). Ischemia and reperfusion did 
not significantly decrease myocardial oxygen con- 
sumption in either group although regional contrac- 
tile function was reduced by approximately 70%. 
The inotropic effect of dobutamine was associated 
with an increase in myocardial oxygen consumption 
from 7.2 _+ 0.2 to 12.0 _+ 0.4 ml/min per 100 gm (p < 
0.05). On cessation of the dobutamine infusion, the 
myocardial oxygen consumption returned to prein- 
fusion levels within 20 minutes. In contrast o that 
with dobutamine, the inotropic effect of pyruvate 
was associated with little change in myocardial 
oxygen consumption (from 6.7 _+ 0.3 to 7.2 _+ 0.2 
ml/min per  100 gm). 
Dialysate adenosine levels. Preischemic dialysate 
adenosine levels were similar in both groups. Dialy- 
sate adenosine concentration i creased more than 
20-fold dur!ng ischemia in both groups (14.91 _+ 3.05 
/xmol/L and 13.65 _+ 3.53/xmol/L). During 10 min- 
utes of dobutamine infusion in the stunned heart, 
dialysate adenosine concentrations increased from 
0.47 _+ 0.05 to 0.75 +_ 0.09/xmol/L (Fig. 3,p < 0.05). 
Dialysate inosine levels increased from 1.75 + 0.28 
to 2.09 _+ 0.3 /xmol/L, and hypoxanthine levels 
increased from 11.46 _+ 0.16 to 13.09 2 0.19/xmol/L. 
After a 20-minute washout, adenosine levels re- 
turned to preinfusion values. Intracoronary pyruvate 
infusion did not increase dialysate adenosine (0.58 +_ 
0.08 versus 0.57 _+ 0.07/xmol/L), inosine, or hypo- 
xanthine levels. 
Myocardial phosphorylation potential. The ef- 
fects of dobutamine and pyruvate on the CrP/Cr • Pi 
ratio, which was used as an index of the myocardial 
phosphorylation potential, are illustrated in Fig. 4. 
Both groups had comparable CrP/Cr • Pi ratios and 
total tissue ATP content after 30 minutes of reper- 
fusion. In the stunned heart, intravenous dobut- 
amine infusion decreased the CrP/Cr • Pi ratio from 
0.17 _+ 0.02 to 0.09 2 0.02. Dobutamine did not alter 
venous pH (7.33 2 0.01 versus 7.34 2 0.02), carbon 
dioxide tension levels (56.22 _+ 2.72 versus 54.8 _+ 
4.32 mm Hg), HCO 3- levels (33.2 -+ 0.6 versus 31.8 
_+ 1.2 mmol/L), or tissue ATP content (3.84 2 0.27 
/zmol/gm wet weight before infusion versus 3.79 _+ 
0.26 bcmol/gm wet weight after infusion). 
In contrast o dobutamine, intracoronary pyru- 
vate infusion resulted in more than a twofold in- 
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Fig. 2. Myocardial oxygen consumption (MVO9 at baseline (Base), reperfusion (30' RP), intravenous 
dobutamine (DOB) administration, i tracoronary p ruvate (PYR) infusion, and 20 minutes of recovery. 
Myocardial oxygen consumption is expressed as milliliters per minute per 100 gm left ventricular tissue. 
Values are expressed as mean plus or minus standard error of mean. *p < 0.05 versus reperfusion. 
crease in the CrP/Cr. Pi ratio from 0.20 _+ 0.03 to 
0.55 ± 0.08. The increase in the CrP/Cr • Pi ratio was 
not associated with measurable changes in venous 
pH (7.35 ± 0.04 versus 7.34 ± 0.01), HCO 3- level 
(32.1 ± 0.7 versus 34.1 ± 1.06 mmol/L), carbon 
dioxide tension level (59.9 ± 1.1 versus 62.0 ± 1.5 
mm Hg), or tissue ATP content (3.56 ± 0.22 versus 
3.69 ± 0.36/zmol/gm wet weight). 
Discussion 
The results of this study indicate that the positive 
inotropic effect of dobutamine in the stunned heart 
is associated with increased myocardial adenosine 
release and decreased phosphorylation potential. In 
contrast, the positive inotropic effect of pyruvate 
had no effect on interstitial adenosine levels and 
significantly increased the phosphorylation poten- 
tial. These findings suggest that dobutamine, in 
contrast o pyruvate, increases function in stunned 
myocardium at the expense of myocardial energet- 
ics. 
The rationale for treating the stunned heart with 
positive inotropic agents such as dobutamine is 
based on the fact that postischemic dysfunction may 
be related to decreased myofibrillar Ca 2+ sensitivi- 
ty. 4 The inotropic effect of dobutamine is mediated 
by the 13-adrenergic receptor-induced increase in 
adenylyl cyclase activity and a concomitant increase 
in cytosolic alcium level 16 and increased phosphor- 
ylation of regulatory and contractile proteins, t7 
However, the metabolic effects associated with such 
mechanisms may not be beneficial to the stunned 
heart. The inotropic effect of dobutamine is associ- 
ated with a considerable increase in oxygen con- 
sumption and markedly elevated interstitial adeno- 
sine levels, which indicate nhanced metabolic stress 
on the cardiomyocytes. 7' 18 These effects may de- 
energize already jeopardized stunned myocardium, 
which exhibits elevated oxygen consumption relative 
to its depressed contractile stateJ 9 Dobutamine also 
increases intracellular Ca 2+ at a time when the 
stunned heart may have a reduced ability to regulate 
intracellular Ca 2+, that is, when it has reduced 
sarcoplasmic reticulum Ca2+-ATPase activity) 
Moreover, the potential effects of dobutamine on 
reducing calcium sensitivity may be another unde- 
sirable side effect associated with its inotropic effect, 
because stunning itself is associated with reduced 
myofibrillar Ca 2÷ sensitivity. 4 
Myocardial phosphorylation potential and con- 
tractile function. The energy that is available to 
intracellular ion pumps, contractile proteins, and 
other ATP hydrolytic reactions is determined by the 
myocardial phosphorylation potential. This param- 
eter monitors the Gibbs free energy change of ATP 
hydrolysis as shown in the equation 
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Fig: 3. Effects of intravenous dobutamine (DOB) and intracoronary p ruvate (PYR) on dialysate adenosine 
concentration ([ADO]). Ten-minute dialysate samples were collected before ischemia (Base), at 20 to 30 
minutes of reperfusion (30' RP), during 10-minute dobutamine orpyruvate infusions, and during 10 to 20 
minutes of recovery from infusions. Values (micromoles) are expressed as mean plus or minus standard 
error of mean. *p < 0.05 versus reperfusion. 
[ADP] [Pi] 
GAT P = GOATP q- RT- Ln [ATP] 
where AO ° is the standard free energy change of 
ATP hydrolysis, R is gas constant, and T is absolute 
temperature. 
Under many conditions, because AG O is relatively 
constant, the main determinant of the equation is 
the [ATP]/[ADPJ • [Pi] ratio. Direct measurement of 
cellular myocardial phosphorylation potential is 
complicated by the fact that intracellular ADP is 
primarily bound to myofibrils and compartmented 
between cytosol and mitochondria. 2°'2] However, 
the CrP/Ci • Pi ratio can be accepted as an index for 
cytosolic phosphorylation potential under various 
conditions: as shown in the equation 
[ATP] [CrP] [H + ] 
[~ADP]. [Pi] = [Cr]" [Pi]" Keq 
where Keq is the pH and Mg 2+ dependent equilib- 
rium constant of creatine kinase. This equation is 
based on the creatine kinase reaction at equilibri- 
um. 2° Measurement of levels of creatine phosphate, 
creatine, and inorganic phosphate can be accom- 
plished by measuring the respective total tissue 
contents because creatine phosphate, creatine, and 
the bulk of inorganic phosphate are located primar- 
ily in the cytosol. 2] 
Although it has been reported that isolated per- 
fused hearts exhibit lower phosphorylation potential 
after ischemia, 1° it is not known what role myocar- 
dial phosphorylation potential plays in in vivo myo- 
cardial stunning or what effects inotropic agents 
have on phosphorylation potential under such con- 
ditions. The potential side effects of /3-adrenergic 
receptor agonists used in tile management of post- 
ischemic dysfunction have been studied by several 
investigators; however, their effects on myocardial 
phosphorylation potential have not been fully ad- 
dressed. Bolli and associates z2tested isoproterenol 
(0.1 /xg/kg per minute) for 30 minutes in stunned 
myocardium in regard to regional function; how- 
ever, they did not measure high-energy phosphates. 
Arnold and associates 23reported that infusion of 
dopamine for 3 hours did not increase infarct size 
after 2 hours of ischemia nd 45 minutes of reper- 
fusion. Although they reported no change in ATP 
and creatine phosphate content as a result of dobut- 
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Fig. 4. CrP/Cr. Pi ratio at 30 minutes of reperfusion (30' RP) and during 10 minutes of intravenous 
dobutamine (DOB) or intracoronary p ruvate (PYR) infusion. Values are expressed as mean plus or minus 
standard error of mean. *p < 0.05 versus reperfusion. 
amine infusion, they did not measure creatine and 
inorganic phosphate contents, which are crucial to 
the assessment of myocardial phosphorylation po- 
tential. In accord with our data, Buser and col- 
leagues, 24 with the use of noninvasive 31p nuclear 
magnetic resonance techniques, reported that do- 
butamine administration decreased the CrP/P i ratio. 
Thus it is unlikely that the observed CrP/Cr.P i
decrease observed in this study was an artifact of the 
multiple biopsy protocol; indeed biopsy samples 
were first taken from the apical region such that the 
blood supply to the proximal regions, from which 
subsequent biopsy samples were taken, was not 
compromised. 
Although Bolli and associates 22 reported that 
regional function in stunned canine myocardium did 
not deteriorate after cessation of isoproterenol in- 
fusion, in this study regional function in stunned 
porcine myocardium decreased tO less than preinfu- 
sion levels after cessation of dobutamine treatment. 
It is likely that regional function would have re- 
turned to levels similar to those before dobutamine 
infusion, but we only monitored the animals for 20 
minutes after dobutamine administration. Because 
SWT is preload and afterload dependent, it is 
possible that this effect was not a true decrease in 
contractility. However, the observations that dobut- 
amine increased interstitial fluid adenosine levels 
and decreased phosphorylation potential suggest 
that this effect may have been related to the addi- 
tional energetic stress caused by dobutamine in the 
stunned heart. The reduction after dobutamine in- 
fusion in SWT occurred only in the stunned LAD 
bed, inasmuch as SWT in the nonischemic left 
circumflex artery bed returned to preinfusion levels 
after intravenous dobutamine infusion. Pyruvate 
infusion increased contractile function comparable 
to that with dobutamine, but SWT did not deterio- 
rate after cessation of the pyruvate infusion, most 
likely because of the salutary effect of this agent on 
myocardial phosphorylation potential. 
The exact link between myocardial phosphoryla- 
tion potential and contractile function remains un- 
known. Enhanced myocardial energetics benefit all 
intracellular energy-dependent reactions uch as ion 
pumps, contractile proteins, and metabolic synthetic 
proteins. The calculated minimum energy required 
to maintain intracellular calcium homeostasis is 
about 52 kJ/mol, and normal physiologic AGAT e is 
about 60 kJ/mol. Mallet and Biinger 2s recently 
reported that the inotropic effect of pyruvate in 
isolated perfused guinea pig hearts was associated 
with improved sarcoplasmic reticulum calcium han- 
dling. Therefore, considering the decreased sarco- 
plasmic reticulum function and impaired energy 
metabolism in stunned myocardium, pyruvate may 
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be of value in the treatment of myocardial stunning 
on the basis of its beneficial effects on both function 
and energy metabolism. 
Limitations. One potential limitation in using the 
CrP/Cr. Pi ratio to assess myocardial phosphoryla- 
tion potential is that creatine kinase depends on 
intracellular pH and Mg2+. 1°' 2o The stability of the 
regional venous pH, HCO 3 , and carbon dioxide 
tension levels during our protocols implies relatively 
stable intracellular pH level. Moreover, that ATP, 
the main chelator of [Mg2+]i, did not change during 
the dobutamine and pyruvate infusions uggests that 
there were no major alterations in [Mg2+]i . 
Another limitation in this study was the assess- 
ment of regional ventricular function by SWT, 
which is dependent on preload, afterload, and 
heart rate. Because intracoronary pyruvate had no 
effect on any of these parameters (Table I) it is 
likely that the increase in LAD SWT with pyru- 
vate was indicative of increased contractility. Do- 
butamine initially increased arterial pressure, but 
after l0 minutes of infusion the only systemic 
effect of dobutamine was an increase in heart rate, 
an effect that would decrease SWT. The decrease 
in SWT after termination of the dobutamine 
infusion was most likely because of an imbalance 
in oxygen supply and demand as evidenced by the 
increase in interstitial adenosine and the decrease 
in phosphorylation potential. Although it is likely 
that this was only a transient effect and may have 
been caused by the dobutamine-induced increase 
in heart rate. we have observed in similar studies 
that lower doses of dobutamine that have little 
effect on heart rate also decrease myocardial 
phosphorylation potential. 
Finally. it must be pointed out that the results in 
this study provide no insight into the relative po- 
tency of pyruvate versus dobutamine, because these 
agents were infused via different routes; that is, 
dobutamine intravenously versus pyruvate by intra- 
coronary infusion. Intracoronary infusion of dobut- 
amine caused asynchronous wall motion in the area 
of interest, which has been observed in other in vivo 
regional ischem~c models. 26 Pyruvate was infused 
locally to minimize potential confounding effects of 
high systemic levels of pyruvate, which is an area not 
well explored at the present. 
Conclusion. The results from this study highlight 
the dilemma in the treatment of myocardial stun- 
ning with dobutamine. Dobutamine is one of the 
most potent inotropes clinically available, but its 
possible deleterious effects on myocardial energetics 
are of major concern. The findings in this study 
emphasize the need to elucidate the optimal inotro- 
pic therapy for the stunned heart. 
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Discussion 
Dr. Sidney Levitsky (Boston, Mass.). I am particularly 
pleased with this report because it substantiates a per- 
sonal, long-held hypothesis that all inotropic agents pres- 
ently approved by the Food and Drug Administration 
administered after cardiac operation are potentially dele- 
terious to myocardial function because they increase 
myocardial oxygen consumption during the period of cell 
membrane instability associated with reperfusion-induced 
myocardial stunning. These adverse effects are potenti- 
ated in the patient undergoing coronary revascularization 
who, despite our attempts at total revascularization, has 
regional areas that are incompletely revascularized and 
energetically deficient. 
I have several questions. Are you able to discriminate 
whether the increase in myocardial oxygen consumption 
noted in the dobutamine group was associated with an 
increase in the contractile state of the heart or was related 
to an increase in the heart rate that was not noted with the 
pyruvate group? This question could have been clarified if 
the authors had blocked the sinoatrial or the atrioventric- 
ular node in the experimental preparation and controlled 
the heart rate. 
Dr. Pedro del Nido and his associates in 1992 per- 
formed a similar experiment with use of a Langendorff- 
perfused model and did not find depression of myocardial 
function after dobutamine infusion. Was this related to 
differing function measurements because they used a 
rate-pressure product and you used systolic wall thicken- 
ing, or was this related to a change in the geometric 
configuration of the left ventricular cavity particularly in 
the left circumflex artery area, which was the control 
group? Similar to the present report, del Nido found that 
pyruvate improved the energetic state of the heart com- 
pared with results with dobutamine. 
Finally, there appears to be increasing experimental 
evidence that pyruvate may be the inotropic drug of 
choice to treat myocardial stunning after operation. Do 
you know of any potential adverse effects that would 
prevent its clinical use? 
Dr. Zhou. In response to the first question, it is proba- 
ble that the increase in myocardial oxygen consumption 
during dobutamine infusion was caused in part by the 
approximately 50% increase in heart rate. However, in 
additional studies in the stunned heart we have observed 
that lower doses of dobutamine, which have little effect on 
heart rate, decrease myocardial phosphorylation poten- 
tial, suggesting that myocardial oxygen consumption i - 
creased. With respect o the second question regarding 
functional depression after cessation of dobutamine infu- 
sion, we agree that this observation may be a result of the 
conditions used in this study. Ventricular function was 
assessed by SWT and the hearts were monitored for only 
20 minutes after dobutamine administration was discon- 
tinued. More recent studies in our laboratory indicate that 
30 minutes after cessation of dobutamine administration, 
regional contractility, measured by the slope of the end- 
systolic pressure thickness relationship, is similar to that 
before dobutamine administration. 
Regarding the clinical utility of pyruvate, it is not known 
to what extent plasma pyruvate levels need to be elevated 
to exert a positive inotropic effect nor what effects pro- 
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longed pyruvate infusion has on systemic hemodynamics 
or metabolism. One potential adverse effect may be 
alkalosis because pyruvate is cotransported across the 
sarcolemma with hydrogen ions. 
Dr. Dimitri Novitzky (Tampa, Fla.). We have studied 
the stunned myocardium in dogs with use of pressure- 
volume relationships looking at the area at risk and the 
nonischemic myocardium with sonomicrometers. We have 
observed after 30 minutes of reperfusion of the heart that 
the dyskinetic area at risk (stunned myocardium) after 
triiodothyronine administration recovers to control status 
(before stunning). We notice also no impact of T3 on the 
nonischemic myocardium. This study with the use of 
pressure-volume r lationships shows clearly an excellent 
recovery of the left ventricular arterial coupling; therefore 
T 3 has also a significant peripheral effect. 
T 3 activates the pyruvate dehydrogenase ystem, allow- 
ing more pyruvate to get into the mitochondria, nd it also 
activates the adenylate nucleotide transferase, allowing 
ATP transfer out of the mitochondria and ADP back into 
it. Do you think that by increasing pyruvate availability to 
the mitochondria that the observed inotropic effect is an 
indirect one increasing substrate for the aerobic metabo- 
lism resulting in high-energy phosphate production, rather 
than a direct inotropic effect on the saracomere? With 
administration of T 3 we have observed similar effects on 
the myocardium and also a synergistic effect of T 3 and the 
catecholamines on the beta receptors. 
Dr. Zhou. We do not know at the present he exact 
mechanism of the positive inotropic effect of pyruvate. 
With respect to pyruvate dehydrogenase, it has been 
reported that in isolated perfused hearts, pyruvate is more 
effective in attenuating stunning than activating pyruvate 
dehydrogenase with sodium dichloroacetate. One of our 
working hypotheses i that the pyruvate-induced increase 
in phosphorylation potential provides more energy to 
drive the highly energy-dependent sarcoplasmic reticulum 
Ca 2+-ATPase, which has been reported to be depressed in
stunned myocardium. In fact, Mallet and Bringer recently 
reported that the positive inotropic effect of pyruvate in 
isolated guinea pig hearts was associated with increased 
sarcoplasmic reticulum calcium handling. 
Dr. Gerald D. Buekberg (Los Angeles, Calif.). My 
question relates to whether the authors think that pyru- 
vate is an inotropic stimulus or that it restores depleted 
substrate. Stated differently, are we whipping a tired horse 
in one situation and are we feeding one in another? I
suppose that can be answered by determining whether 
pyruvate increased contractility of the nonischemic seg- 
ment. These observations would help determine whether 
these results reflect a restoration of a depleted substrate 
from ischemia or direct inotropism by an agent hat effects 
calcium handling in a different way. 
Dr. Zhou. As stated in response to the previous ques- 
tion, we do not know the exact mechanism of the positive 
inotropic effect of pyruvate. However, it is unlikely that 
pyruvate is acting by merely restoring depleted substrates, 
because we have previously reported that pyruvate xerts 
similar inotropic effects in nonstunned canine myocar- 
dium. In addition, in both the normal and stunned heart, 
the onset of the positive inotropic effect occurs within 1 to 
2 minutes after initiation of the pyruvate infusion and 
dissipates just as rapidly when the pyruvate infusion is 
terminated. 
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